A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, PARALLEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE ASCENDING ORAL DOSES OF PF-07328948 IN HEALTHY ADULT PARTICIPANTS
Latest Information Update: 23 Jul 2024
At a glance
- Drugs PF 07328948 (Primary) ; PF 07328948 (Primary)
- Indications Heart failure
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Pfizer
Most Recent Events
- 19 Jul 2024 Status changed from recruiting to completed.
- 04 Apr 2024 Planned End Date changed from 26 Jun 2024 to 10 Jul 2024.
- 04 Apr 2024 Planned primary completion date changed from 26 Jun 2024 to 10 Jul 2024.